Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
INAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.98 - $21.21
Previous CloseN/A
Volume363.43K
Average Volume (3M)134.14K
Market Cap
$10.31M
Enterprise Value-$1.50M
Total Cash (Recent Filing)$11.89M
Total Debt (Recent Filing)$4.27M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 06, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding4,539,717
10 Day Avg. Volume115,671
30 Day Avg. Volume134,142
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.38
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$3.00Price Target Upside32.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessMultiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.
Preclinical DataIN8bio presented promising preclinical data with their CD19 targeting γδ TCE (INB-619) showing deep B cell depletion in lupus patient blood samples.
Safety ProfileNo new safety concerns were reported. No DLT, ICANS, CRS, or DRI-.
Bears Say
Clinical Trial SuspensionIN8bio suspended enrollment in their clinical trials evaluating INB-200 and '400 in GBM last year, and is actively exploring strategic partnerships and other potential opportunities to further develop this program.
Response VariabilitySome antibodies remained in the samples, particularly from Donor 3, where B cell depletion was observed after 6 days, indicating variability in response time.
IN8bio News
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $1.98 and its highest was $21.21 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is $10.31M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Nov 06, 2025 which is in 85 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Aug 07, 2025. The company reported -$1.24 earnings per share for the quarter, beating the consensus estimate of -$1.725 by $0.485.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -1.22.
How many shares outstanding does IN8bio have?
IN8bio has 4,539,717 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$1.24 in its last earnings report, beating expectations of -$1.725. Following the earnings report the stock price went up 7.442%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
IN8bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (32.16% Upside)
$3.00 (32.16% Upside)
Hedge Fund Trend
Decreased
By 618.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.17%
12-Months-Change
Fundamentals
Return on Equity
-165.56%
Trailing 12-Months
Asset Growth
-13.89%
Trailing 12-Months
Company Description
IN8bio
IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies for the treatment of cancer. The company operates in the biotechnology and healthcare sectors, leveraging its proprietary technology platform to create cell-based immunotherapies aimed at targeting both solid tumors and hematologic malignancies. IN8bio's core products are designed to harness the power of the immune system to recognize and attack cancer cells, offering potential therapeutic options for patients with limited treatment alternatives.
INAB Stock 12 Month Forecast
Average Price Target
$3.00
▲(32.16% Upside)
Technical Analysis
Imunon
―
MEI Pharma
―
Phio Pharmaceuticals
―
Bolt Biotherapeutics
―
SAB Biotherapeutics
―
Ownership Overview
23.83% Insiders
2.08% Mutual Funds
14.52% Other Institutional Investors
57.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---